San Francisco startup Structure Therapeutics is likewise working on an oral, after-day-to-day GLP-1 drug called GSBR-1290—the drug surpassed Wall Avenue’s expectations in June each time a mid-stage study showed regular weight loss of about 6% and it programs to start out One more mid-phase trial toward the top of this 12 months—that founder a